Interferon is an immune stimulating agent. According to an article recently published in the Annals of Surgery, administration of interferon following surgery may improve survival among patients with advanced hepatitis B-related hepatocelluar carcinoma.

Hepatocelluar carcinoma (HCC) is the most common type of liver cancer. Unfortunately for this disease, recurrences often happen after surgical removal of the cancer. Researchers continue to evaluate ways to reduce these recurrences.

A clinical trial was conducted to evaluate the use of interferon following surgery in patients with HCC. The trial included 80 patients, one group received the interferon after surgery and the other group received no further treatment. The researchers found that the group treated with interferon experienced better survival rates.

Almost 19,000 cases of primary liver cancer will be diagnosed in the United States this year according to The American Cancer Society. This type of cancer is twice as common in men as in women. Over 16,000 patients will die of their liver cancer by the end of 2006.

The liver is responsible for many vital roles in our body. It plays an important role in removing toxic waste, stores many nutrients absorbed from the intestines and can also make some of the clotting factors needed to stop bleeding from an injury. The liver is made up of several different types of cells. The tumors that develop in the liver can either be benign or cancerous. Benign tumors of the liver include hemangioma, hepatic adenomas and focal nodular hyperplasia.

The most common form of liver cancer is hepatocellular carcinoma. It begins in the main type of liver cell and three out of four patients diagnosed with primary liver cancer are of this type. A type of liver cancer that is rare but has a better prognosis than other forms of liver cancer is called fibrolamellar liver cancer. Cholangiocarcinomas, another form of liver cancer is usually treated the same as hepatocellular carcinoma.

Many times when the cancer is found in the liver it did not begin there but is metastasis from another primary tumor in the body. These tumors are not considered primary liver cancer and are not treated as such, they will be treated based on where the primary tumor began. If you have metastasis to the liver from lung cancer you will still be treated with drugs that kill lung cancer tumors.

When cancer originates in the liver it is called hepatocellular carcinoma (HCC). In advanced HCC the cancer has spread to distant places in the body.

Biological pathways that are believed to be associated with cancer growth and spread can be targeted by Nexavar. A clinical trial was conducted consisting of 137 patients who have received no prior therapy and were unable to undergo the surgical removal of their cancer.

According to the article in the Journal of Clinical Oncology, Nexavar may provide anticancer activity in some patients with liver cancer and is well tolerated.

Also, a measure of 18 genes that were identified can help predict who will benefit from the drug Nexavar. Future clinical trials are being planned to evaluate the use of Nexavar in advanced hepatocellular carcinoma patients.